EP Vantage Half-Year Reviews 2014

Mood lifts for Medtech in first half of 2014 while Pharma sector faces new struggles

EP Vantage EP Vantage Pharma & Biotech Half-Year Review 2014

Based on EvaluatePharma® market intelligence, EP Vantage Pharma & Biotech Half-Year Review 2014 identifies the key trends that defined the pharmaceutical industry in the first half of 2014. 

An M&A frenzy that accounted for nearly $90 billion of equity set the pace for the first half of 2014 in the pharma and biotech sectors, but a slowdown in IPOs and six months of volatile market activity could tarnish the year’s shimmering start.

Download your complimentary copy of EP Vantage Pharma & Biotech Half-Year Review 2014.

EP Vantage EP Vantage Medtech Half-Year Review 2014

EP Vantage Medtech Half-Year Review 2014, based on EvaluateMedTech™ market intelligence, provides an overview of the medical device and diagnostic sector's performance in the first half of 2014. 

The sun is finally shining on the medtech industry: after a shocking year in which mergers, funding and FDA approvals all slipped badly, the sector is seeing improvements across the board.

Download your complimentary copy of EP Vantage Medtech Half-Year Review 2014.



Copyright © 2015, Evaluate Ltd, All rights reserved.